



## Giaconda Board Changes

**Sydney, NSW, 21 January, 2009** – Giaconda Limited (ASX: GIA), today announced that Mr Chris Bilkey has rejoined the board of directors as a non executive director. Mr. Bilkey was previously the Chairman of the board and left in August, 2006 to pursue other interests.

As well, Prof. Tony Moon has resigned from the board for health reasons.

Chief Executive Officer, Patrick McLean, stated, “We are very pleased to have Chris back with us. His extensive experience in the industry and his valuable contributions during the time of our IPO make his return a very welcome event. We would also like to thank Tony for his assistance and dedication to the Company since joining the Board in 2004. We wish him well and will miss him.”

**ENDS**

### About Giaconda Limited

Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda’s products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda’s products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products; Myoconda<sup>®</sup> for the treatment of MAP (*Mycobacterium avium ss paratuberculosis*) infection in Crohn’s Disease and Heliconda<sup>®</sup> for the treatment of resistant *Helicobacter pylori* infection.

*Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.*

### CONTACT:

<b>Giaconda Limited</b>
Patrick McLean Chief Executive Officer and acting Chairman
T: +61 (0)2 9370 0069
<a href="mailto:pmclean@giacondalimited.com">pmclean@giacondalimited.com</a>